Rising aging population, increasing incidences of lifestyle diseases, gradual demand for efficient and safe medication with no side effects, and treatment of diseases having a limited success rate are driving the growth of the global Human Microbiome Market. The market is an emerging market with abundant opportunities and is expected to flourish within five to seven years owing to a number of products currently under the clinical trial phase. In this report, the global market is divided into three major segments namely, application, disease, and product.
Restraints:
- Lack of Expertise and Detailed Research
- Barriers in Proving the Causal Link Between Dysbiosis and Disease
Opportunities:
- Investigational New Drug (IND) Requirements for Fecal Microbiota
- Increasing Collaborations Create Growth Opportunities
Challenge:
- Government Regulations
Burning Issues:
- Abundant Opportunities in the Human Microbiome Field and Tremendous Research Investments
- Development of Human Microbiome Therapeutic Products
Read Some Interesting Facts About "Human Microbiome Research - Global Industry Forecasts to 2025", Here; Download PDF Brochure@ http://bit.ly/2sYazsd
Global Industry Segmentation
On the basis of disease, the human microbiome market comprises of obesity, diabetes, autoimmune disorders, acute diarrhea, cancer, mental disorders, and other diseases. In 2022, the acute diarrhea segment is expected to account for the largest share and is estimated to grow at the highest CAGR during the forecast period (2022–2025).
On the basis of product, the human microbiome research spending market is characterized into instruments and consumables. The instruments segment is further divided into laboratory instruments and analyzers, while, the consumables segment is further bifurcated into kits and reagents. The consumables segment is estimated to grow at the highest CAGR during the forecast period (2016–2021) owing to the repeated purchases of consumables as compared to instruments.
On the basis of technology, the human microbiome research spending market is divided into cell culture technology, high-throughput technology, omics technology, and computational tools. The cell culture technology segment is expected to account for the largest share of the global human microbiome research spending technology market in 2016. The large share can be attributed to the increasing R&D initiatives in the field of human microbiome.
Europe is expected to account for the largest share of the global human microbiome market in 2022. The large share of this region can be attributed to its significant presence in the probiotics and prebiotics fields and the acceptance of these products by its population.
Enterome Bioscience (France), Yakult (Japan), DuPont (U.S.), Metabiomics Corporation (U.S.), ViThera Pharmaceuticals (U.S.), Second Genome Inc. (U.S.), MicroBiome Therapeutics LLC (U.S.), Vedanta BioSciences (U.S.), Osel, Inc. (U.S.), and Merck (U.S.) are the major players in the human microbiome market. Domination of the individual segments in this market will depend on the core competencies of different players.
Companies that launch products targeted at specific indications in the human microbiome market are likely to maintain their positions in this market.
Pfizer is one such company; it releases medicines and vaccines for specific indications. The firm also entered into an agreement with Second Genome for microbiome research in obesity and metabolic disorders.
Companies in the human microbiome market are majorly focusing on expanding and entering segments for new indications and technology. The key strategy is to expand market share through acquisitions and connect financially with firms having common values and goals. To gain maximum market share, companies have been aggressively signing agreements, collaborations, and partnerships with third-party vendors. Enterome Bioscience is one such company the company focuses on developing biomarkers, companion diagnostic kits, and therapeutic solutions.
Major players that adopted this strategy include Second Genome (U.S.), Enterome Bioscience (France), Vedanta Bioscience (U.S.), and Osel, Inc. (U.S.). In April 2016, Enterome entered an agreement with Vertex Pharmaceuticals Inc. (U.S.) to research, develop, and commercialize novel small molecule FimH antagonists, to be utilized in the treatment of inflammatory bowel diseases (IBD).
Companies in the Asia-Pacific regions are also entering the field of microbiome. Yakult Honsha Co., Ltd. is one such company which is engaged in manufacturing and marketing food and beverage products. The company operates through three business segments, namely, Food and Beverages, Pharmaceuticals, and Others. The Food and Beverages segment includes juices, soft drinks, and healthy foods. This segment also includes probiotic drinks that contain Lactobacillus casei, a bacterium which improves intestinal function and immunity.
No comments:
Post a Comment